Image source: Shutterstock

Highlights

  • Hims & Hers’ FY24 revenue surged 69.3% YoY, reaching USD 14.76 million, driven by higher subscriber growth and expanded offerings like weight loss services
  • Net Income flipped from a loss in FY23 to USD 1.26 million in FY24, boosted by higher revenues and a one-time USD 68 million tax benefit
  • Hims & Hers projects Q1 revenue between USD 520 million to USD 540 million, with full-year revenue forecasted at USD 2.3 billion to USD 2.4 billion

Hims & Hers Health (NYSE:HIMS) provides a user-focused platform that connects individuals with healthcare providers, offering digital prescriptions, cloud-based pharmacy services, and personalized care through a clinically integrated system.

In the financial year 2024 (FY24), the company saw a significant 69.3% YoY increase in revenues, reaching USD 14.76 million, driven by higher subscriber growth, higher average order values, and the successful expansion of new services like weight loss offerings.

During the reported period, net income rose to USD 1.26 million from a loss of USD 23,546 in FY23. This improvement was mainly fueled by higher revenues and a one-time USD 68 million benefit from releasing the valuation allowance on deferred tax assets, despite some offsetting current tax expenses.

Free cash flow surged by 322.1% YoY to USD 1.98 million in FY24. Additionally, cash and cash equivalents grew by 128.2% YoY, reaching USD 2.2 million due to higher operating cash flows driven by increased revenue and improved margins, which supported ongoing investments and strategic initiatives.

Company Outlook

For Q1, the company expects revenue to fall between USD 520 million and USD 540 million, with adjusted EBITDA projected to be in the range of USD 55 million to USD 65 million, reflecting a margin of 11% to 12%. For the full year 2025, the company anticipates revenue between USD 2.3 billion and USD 2.4 billion, with adjusted EBITDA expected to range from USD 270 million to USD 320 million, resulting in a margin of 12% to 13%.

Top 10 Shareholders

The top 10 shareholders of HIMS collectively hold approximately 49.91% of the company’s total shares, indicating a concentrated ownership structure. BlackRock Institutional Trust Company, N.A. and The Vanguard Group, Inc. are the largest shareholders, owning 12.92% and 9.46%, respectively.

Stock Information

HIMS stock has appreciated by 24.92% over the past six months but declined by 28.60% in the last month. The 52-week high and low are USD 72.98 and USD 11.20, respectively, with a closing price of USD 26.71 on April 23, 2025.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is April 23, 2025. The reference data in this report has been partly sourced from EODHD/Others.

 Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.